Topica nails down $27 million Series B in pursuit of fungal infection treatment
This article was originally published in Scrip
Executive Summary
While the yellow-green fungus that infects toenails, known as onychomycosis, may not be a sexy topic of discussion, the potential multibillion market for a drug to fill the current unmet need was enough of an alluring siren call to entice investors to lay down a bundle of cash to back Topica Pharmaceuticals' development of its experimental broad-spectrum topical antifungal agent luliconazole to treat the condition.